Tacrolimus versus Cyclosporine Immunosuppression in Pediatric Renal Transplantation: Pharmacokinetic Consideration.
- Author:
Jung Sue KIM
1
Author Information
1. Department of Pediatrics, Cheongju St.Mary's Hospital, Cheongju, Korea. youngped@hotmail.com
- Publication Type:Review
- Keywords:
Cyclosporine;
Tacrolimus;
Pharmacokinetics
- MeSH:
Area Under Curve;
Biological Availability;
Child, Preschool;
Cyclosporine*;
Cytochrome P-450 Enzyme System;
Drug Monitoring;
Humans;
Immunosuppression*;
Immunosuppressive Agents;
Kidney Transplantation*;
Pharmacokinetics;
Tacrolimus*;
Transplantation
- From:Korean Journal of Pediatrics
2005;48(5):476-480
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Immunosuppressive therapy in pediatric renal transplant recipients is changing consequence of the increasing number of available immunosuppressive agents. The optimal use of immunosuppressive agents requires a thorough understanding of the pharmacokinetic characteristics, but the information on the pharmacokinetic characteristics of these drugs in pediatric transplant recipients is still limited. In general, patients younger than 5 years old show higher clearance rates, therefore the need for higher dosages in younger patients seems evident. By the therapeutic drug monitoring, trough(Cmin) and peak level(Cmax) are measured and the area under the blood concentration-time curve(AUC), which is taken as being representative of total systemic exposure can be calculated. Cyclosporine A (CSA) has poor bioavailability, which contributes to high inter- and intra-patient pharmacokinetic variability. CSA concentration measured 2 hours after administration(C2) has better correlation with the AUC than Cmin and is an alternative technique that predicts the AUC. Tacrolimus(Tac) has a great deal of inter-individual variability like CSA but intra-individual variability in systemic exposure is considered to be low. Both CSA and Tac are metabolized by a cytochrome P-450 enzyme isoform(CYP3A4). We should consider changing the dosages when CSA or Tac is used in combination with the medicines that inhibit or induce the CYP3A4. In case of steroid-free immunosuppressive therapy, the blood concentration of Tac should be frequently checked and dosage adjustment may be needed.
